Day 3 - Thursday, November 20, 2025Thursday, 20 November 2025 - ET (Eastern Time, GMT-05:00)

Potential Medicaid budget reductions could significantly impact patient affordability and manufacturer assistance programs. This session will examine state-specific Medicaid changes, federal policy updates and strategies that manufacturers can employ to mitigate the effects on reimbursement and patient access.

• Understand how patient access programs evolve over time, and in turn, may look different at launch vs mid life cycle vs end life cycle
• Pinpoint the KPIs and metrics to measure success at each stage, with an understanding that ROI cannot be the sole defining factor
• Discuss best practices to ensure that you are maintaining a robust patient access strategy throughout the programs entire lifecycle
• Identify the key measurables to look for in order to adjust and better align with brand strategy

With PBM revenue models shifting and legislative reform on the table, market access and copay teams must prepare for new contracting hurdles, formulary access restrictions and changing cost-sharing dynamics. As PBMs move away from rebates toward fee-based structures, manufacturers will see a ripple effect in copay design, accumulators/maximizers and patient affordability strategies.

• Learn how PBM strategies impact manufacturer copay programs and how to adjust for higher patient cost-sharing
• Understand formulary placement shifts and what to expect in payer negotiations.
• Legislative updates – will PBM reform materialize and how should manufacturers prepare?

As precision medicine and biomarker-driven therapies expand, seamless collaboration between manufacturers and diagnostic companies is more critical than ever. Effective partnerships can accelerate therapy adoption, streamline patient identification and enhance market access strategies. This session explores best practices for aligning commercialization efforts, navigating reimbursement hurdles and optimizing patient access through diagnostics.